With Amgen having success in having biosimilars approved by fta, i suggest this may further future developments with other biosimilars that with an agreement with UNS may see their technology used to deliver these down the track when being approved by fta, and thus lock in a substantial future revenue stream.This is my take on this , has anyone got a different angle?
- Forums
- ASX - By Stock
- UNS
- Amgen's biosimilar candidate to Humira
Amgen's biosimilar candidate to Humira, page-3
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online